Maridebart cafraglutide
Product Specifications
UNSPSC Description
Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity[1][2].
Target Antigen
GLP Receptor
Type
ADC Related
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/maridebart-cafraglutide.html
Smiles
[Maridebart cafraglutide]
Molecular Weight
153,514 (average)
References & Citations
[1]Bloomgarden Z T. The 2023 WCIRDC: Obesity[J]. Journal of Diabetes, 2024, 16(4).|[2]Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164535/Maridebart-cafraglutide-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164535/
Clinical Information
No Development Reported
CAS Number
2887445-76-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
